Samjin Pharmaceutical said on the 6th that it signed an exclusive domestic supply deal with AI-based medical company Ontact Health for the cardiac ultrasound analysis solution "Sonix Health."
Under the agreement, Samjin Pharmaceutical will handle domestic supply and distribution of the solution. The two companies also plan to promote wider adoption by medical institutions and conduct joint marketing.
Sonix Health is an AI-based automatic cardiac ultrasound analysis solution. It received U.S. Food and Drug Administration (FDA) 510(k) clearance and class 2 medical device certification from the Ministery of Food and Drug Safety.
Conventional cardiac ultrasound readings showed large result variations depending on examiner proficiency, and tests took 60–90 minutes. The company said the solution's "one-click" automatic analysis cuts test time by more than 70%.
The solution provides integrated functions that include reading summaries and recommendations for prescriptions and transfers. As of the end of last year, it was in use at about 3,000 medical institutions in Korea and abroad.
Samjin Pharmaceutical plans to use the deal to expand its Digital Healthcare business. Following its existing electrocardiogram monitoring device "S-Patch Ex," it aims to strengthen its portfolio of cardiovascular diagnostic equipment.